Browse > Article
http://dx.doi.org/10.5762/KAIS.2014.15.5.2971

Effects on the Risk of Cardiovascular Disease in Breast Cancer Patients Received Postoperative Adjuvant Anticancer Therapy  

Yu, Mi-Seon (Department of Pharmacy, Chungnam National University Hospital)
Lee, Tae-Yong (Department of Preventive Medicine and Public Health, School of Medicine, Chungnam National University)
Publication Information
Journal of the Korea Academia-Industrial cooperation Society / v.15, no.5, 2014 , pp. 2971-2980 More about this Journal
Abstract
To find the risk of cardiovascular disease for breast cancer patients received postoperative adjuvant anticancer therapy, this study was investigated the change of serum lipid profile (total cholesterol and trigyiceride) and the 10 year risk score of ischemic heart disease. Medical data of 432 breast cancer patients diagnosed at the breast cancer center in an university hospital from January, 2003 to December, 2006 were collected and analysed. The results showed that the levels of total cholesterol and triglyceride were increased at the points of 2 and 5 years after operation. The margin of increase of total cholesterol was higher in the patients without endocrine therapy compared to them with endocrine therapy, however there were no changes in the level of triglyceride regardless of endocrine therapy. There were also no significant changes in total cholesterol and triglyceride levels between chemotherapy, radiotherapy and endocrine therapy. 10 year-risk score of ischemic heart disease was increased by 0.44%p in the final observation compared to that of a baseline.
Keywords
Adjuvant anticancer therapy; Breast cancer; Cardiovascular disease; Risk;
Citations & Related Records
연도 인용수 순위
  • Reference
1 S. Lewis, "Do endocrine treatments for breast cancer have a negative impact on lipid profiles and cardiovascular risk in postmenopausal women?", American Heart Journal, Vol, 153(2), pp. 182-188, 2007. DOI: http://dx.doi.org/10.1016/j.ahj.2006.10.034   DOI   ScienceOn
2 T. D. Filippatos, E. N. Liberopoulos, N. Pavlidis, et al. "Effects of hormonal treatment on lipis in patients with cancer". Cancer Treatment Reviews, Vol, 35(2), pp. 175-84, 2009. DOI: http://dx.doi.org/10.1016/j.ctrv.2008.09.007   DOI   ScienceOn
3 T. Tominaga, I. Kimijima,, M, Kimura, et al. "Effects of toremifene and tamoxifen on lipid profiles in post-menopausal patients with early breast cancer : Interim results from a Japanese Phase III trial", Japan Journal of Clinical Oncology, Vol, 40(7), pp. 627-633, 2010. DOI: http://dx.doi.org/10.1093/jjco/hyq021   DOI   ScienceOn
4 S. H. Jee, J. W. Song, H. K. Cho, et al. Development of the individualized health risk appraisal model of ischemic heart disease risk in Korea", Journal of Korean Lipid and Atherosclerosis, Vol, 14(2), pp. 153-168, 2004.
5 W. B. Kannel, D. McGee, T. Gordon, "A general cardiovascular risk profile: The Framingham Study", The American Journal of Cardiology, Vol, 38(1), pp. 46-51, 1976. DOI: http://dx.doi.org/10.1016/0002-9149(76)90061-8   DOI   ScienceOn
6 American Joint Committee on Cancer(AJCC), "Cancer staging manual. Sixth ed", Philadelphia(PA), Lippincott Raven Publishers, 2002.
7 National Institute of Health, "The seventh report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure", NIH Publication No. 03-5233, 2003.
8 L. Mosca, H. Mochari, A. Christina, et al. "National study of women's awareness, preventive action, and barriers to cardiovascular health". Circulation, Vol, 113(4), pp. 525-534, 2006. DOI: http://dx.doi.org/10.1161/CIRCULATIONAHA.105. 588103   DOI   ScienceOn
9 Koran Society of Lipidology and Atherosclerosis. "Dyslipidemia treatment guideline, 2nd edition", pp. 6, 2009.
10 S. Moorjani, A. Dupont, F. Labrie, et al. "Changes in plasma lipoproteins during various androgen suppression therapies in men with prostatic carcinoma: effects of orchiectomy, estrogen, and combination treatment with luteinizing hormone-releasing hormone agonist and flutamide", The Journal of Clinical Endocrinology and Metabolism, Vol, 66(2), pp. 314-322, 1988. DOI: http://dx.doi.org/10.1210/jcem-66-2-314   DOI
11 E. J. Schaefer, D. M. Foster, L. A. Zech, et al. "The effects of estrogen administration on plasma lipoprotein metabolism in premenopausal females", The Journal of Clinical Endocrinology and Metabolism, Vol, 57(2), pp. 262-267, 1983. DOI: http://dx.doi.org/10.1210/jcem-57-2-262   DOI
12 H. J. Milionis, E. N. Liberopoulos, M. S. Elisaf, "Tamoxifen-induced hypertriglyceridemia in association with diabetes mellitus", Diabetes and Metabolism, Vol, 27, pp. 160-163, 2001.
13 M. Elisaf, E. Bairaktari, N. Pavlidis, "The influence of tamoxifen on serum triglycerides", Breast, Vol, 9(4), pp. 238, 2000. DOI: http://dx.doi.org/10.1054/brst.1999.0129   DOI   ScienceOn
14 Y. Hozumi, M. Kawano, T. Saito, et al. "Effect of tamoxifen on serum lipid metabolism", The Journal of Clinical Endocrinology and Metabolism, Vol, 83(5), pp. 1633-163, 1998. DOI: http://dx.doi.org/10.1210/jc.83.5.1633   DOI
15 Korean Breast Cancer Society, "2006-2008 Breast cancer facts & figures", pp. 2-14, 2008.
16 National Institute of Health. "Third report of the national cholesterol education program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults final report", Circulation, Vol, 17(24), pp. 3145-3421, 2002.
17 National Cancer Center, "Cancer facts & figures", pp. 8, 2012.
18 A. Jemal, R. Siegel, E. Ward, et al, "Cancer statistics, 2006" CA: Cancer Journal for Clinicians, Vol, 56(2), pp. 106-130, 2006. DOI: http://dx.doi.org/10.3322/canjclin.56.2.106   DOI   ScienceOn
19 A. Howell, J. Cuzick, M. Baum, et al, "Results of the ATAC (Arimidex, Tamoxifen, Alone or Combination) trial after completion of 5years' adjuvant treatment for breast cancer", Lancet, Vol, 365(9453), pp. 60-62, 2005. DOI: http://dx.doi.org/10.1016/S0140-6736(04)17666-6   DOI   ScienceOn
20 D. N. Lloyd-Jones, A. R. Dyer, R. Wang, et al. "Risk factor burden in middle age and lifetime risks for cardiovascular and non-cardiovascular death(Chicago Heart Association Detection Project in Industry)", American Journal of Cardiology, Vol, 99(4), pp. 535-540, 2007. DOI: http://dx.doi.org/10.1016/j.amjcard.2006.09.099   DOI   ScienceOn
21 D. Steinberg, J. L. Witztum, "Lipoproteins and atherogenesis; Current concepts:, The Journal of the American Medical Association, Vol, 264(23), pp. 3047-3052, 1990. DOI: http://dx.doi.org/10.1001/jama.264.23.3047   DOI   ScienceOn
22 W. B. Kannel, W. P. Castelli, T. Gordon, et al. "Serum cholesterol, lipoproteins, and the risk of coronary heart disease. The Framingham Study", Ann Intern Med, 74(1), pp. 1-12, 1971. DOI: http://dx.doi.org/10.7326/0003-4819-74-1-1   DOI   ScienceOn
23 R. J. Glynn, G. J. L'Italien, H. D. Sesson, et al, "Development of predictive models for longterm cardiovascular risk associated with systolic and diastolic blood pressure", Hypertension, Vol, 39(1), pp. 105-110, 2002. DOI: http://dx.doi.org/10.1161/hy1201.097199   DOI   ScienceOn
24 World Health Organization, "World Cancer Report 2008", pp. 212-213, 2010.
25 K. M. Anderson, P. M. Odell, P. W. F. Wilson, et al, "Cardiovascular disease risk profiles", American Heart Journal, Vol, 121, pp. 293-298, 1990. DOI: http://dx.doi.org/10.1016/0002-8703(91)90861-B   DOI   ScienceOn